AN2 Therapeutics Cuts Research Spending As Quarterly Loss Narrows To $8.0 Million
AN2 expects its funds to last into 2029, with enrollment in its global blood-cancer trial expected by year-end.
AN2 Therapeutics, which develops experimental boron-based medicines for blood diseases, infections and cancer, narrowed its third-quarter loss to $8.0 million from $9.4 million a year earlier as research and trial costs fell. Monday’s earnings release puts the company’s funding horizon into 2029 under its current plan, with enrollment in a global epetraborole blood-cancer study expected by year-end.
Lower Costs, More Shares
Research spending totaled $5.7 million, versus $7.0 million in the third quarter of 2025. Lower spending on research, preclinical studies and clinical trials outweighed increases in personnel and manufacturing-related costs.
Administrative expenses declined to $2.9 million from $3.0 million: personnel savings exceeded increases in outside services and other expenses. Interest income rounded to $0.7 million in both periods.
The loss per share fell to $0.17 from $0.31, with a larger share base accompanying the smaller loss. The weighted-average share count used in that calculation was 46,114,047, compared with 30,276,230 a year earlier.
The quarterly research savings did not extend to the full year-to-date period. For the first nine months, research expenses were $18.5 million versus $17.9 million, while net losses were $26.2 million versus $26.5 million. AN2 held $80.2 million in cash, cash equivalents and investments at September 30.
Epetraborole Moves Toward Patient Enrollment
Epetraborole is central to AN2’s clinical work, with studies targeting polycythemia vera, a blood cancer, and Mycobacterium abscessus lung disease. AN2 uses outside manufacturers for trial supplies and licenses epetraborole to Brii Biosciences in China, Hong Kong, Taiwan and Macau in exchange for milestone payments and sales royalties.
Eric Easom, AN2 Therapeutics’ co-founder, chairman, president and CEO, said, “we now have the necessary regulatory clearances from all planned jurisdictions for our global Phase 2 study and are advancing start up activities.” Those jurisdictions include the U.S., Australia and India.
The mid-stage polycythemia vera study will begin with a group receiving a dose predicted to be below the therapeutic level to assess safety and how the drug behaves in patients. A safety committee will then advise on doses for a 28-week evaluation of blood-cell concentration control and reduced need for blood removal. AN2 expects periodic data during 2027; it presented supporting research in August and the study design in October.
Enrollment continues in the investigator-led lung-disease study, which plans to compare epetraborole with placebo in 84 patients across an estimated 10 to 15 U.S. sites. Kevin Winthrop, professor of public health and infectious diseases at Oregon Health and Science University, leads the study. AN2 expects results in late 2027, depending on enrollment, and says positive findings could help shape a subsequent pivotal trial.
Chagas And Bone-Disease Studies Ahead
AN2 is also preparing a mid-stage study of oral AN2-502998 in adults with chronic Chagas disease. The parasitic infection can damage the heart and digestive system; an estimated 10 million people are infected worldwide, including over 300,000 in the U.S. and 200,000 across Europe and Japan. No FDA-approved treatment exists for adults with the disease.
The company’s bone-disease expansion predates Monday’s results. On Wednesday, AN2 selected AN2-504661 for hypophosphatasia, an inherited disorder affecting bone and tooth mineralization. Its planned oral treatment would enter a market where therapy for certain childhood-onset forms requires repeated injections and adult-onset disease has no U.S.-approved treatment.
AN2’s global-health research relies primarily on grants. In September, the Gates Foundation extended funding for its tuberculosis collaboration with GSK. The company also appointed Cameron Trenor as chief medical officer in August.
AN2 plans to begin an early-stage trial of AN2-504661 in the second half of 2027, alongside the expected epetraborole data that year.
Sources
- 8-K Filing — AN2 Therapeutics, Inc. (ANTX) — SEC EDGAR
- Exhibit antx-ex99_1.htm — AN2 Therapeutics, Inc. 8-K exhibit — SEC EDGAR
- AN2 Therapeutics Advances Pipeline With Development Candidate Nomination for Hypophosphatasia (HPP) – Company Announcement - FT.com — Financial Times
- AN2 Therapeutics to Present at Jefferies Global Healthcare Conference in London — businesswire.com